Sanofi’s hexavalent paediatric vaccine gets EU marketing approval

Following the EMA's recommendation back in February, the European Commission has now approved Sanofi Pasteur's 6-in-1 paediatric vaccine Hexyon/Hexacima (DTaP-IPV-HiB-HepB) for primary and booster vaccination of infants from six weeks of age. The vaccine will be sold as Hexyon in Western Europe as a joint venture between Sanofi Pasteur and MSD. In Eastern Europe, however, the vaccine will be called …

Sanofi’s 6-in-1 paediatric shot Hexyon recommended for market approval

Sanofi Pasteur have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended market approval for their 6-in-1 paediatric vaccine Hexyon/Hexacima. The vaccine would be marketed as Hexyon in Western Europe, where it is a joint venture between Sanofi Pasteur and Merck & Co, and Hexacima in Eastern Europe, where it …